⌘K
t
Destiny Pharma plc granted 190,000 share options to Dr. Yuri Martina, Chief Medical Officer, under the Destiny Pharma plc 2020 Long Term Incentive Plan. The options were granted on 8 June 2022 with an exercise price of £0.46 per ordinary share. These options will vest on 8 June 2025.
| Date | 8 Jun 2022 |
| Time | 07:00:10 |
| Category | Director/PDMR dealings |
| ID | 0620O |
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of share options
Brighton, United Kingdom - 8 June 2022 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over 190,000 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following PDMR.
|
Name |
Position |
Total number of Options granted under award |
Total Options held after the grant |
|
Dr Yuri Martina |
Chief Medical Officer |
190,000 |
190,000 |
The Options have been granted with an exercise price of £0.46 and will vest on 8 June 2025. The Options were granted under award agreements that incorporated the terms of the Plan.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Manel Mateus /Vici Rabbetts
+44 (0) 208 078 4357
finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit www.destinypharma.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Yuri Martina |
|
2. |
Reason for the Notification |
|
|
a) |
Position/status |
Chief Medical Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Destiny Pharma plc |
|
b) |
LEI |
213800O9WH9Z38EHAC95 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the Financial instrument, type of instrument |
Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
|
Identification code |
DEST GB00BDHSP575 |
|
|
b) |
Nature of the transaction |
Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
|
c) |
Price(s) and volume(s) |
£0.46 pence exercise price per Ordinary Share 190,000 Ordinary Shares |
|
d) |
Aggregated information: Aggregated volume Price |
See 4c) above
|
|
e) |
Date of the transaction |
8 June 2022 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |